Targetome Overview

  • Founded
  • 2010
Founded
  • Status
  • Out of Business
  • Latest Deal Type
  • Out of Business

Targetome General Information

Description

Developer of affinity-based targeted therapies intended to be used for the diagnosis of pancreatic cancer. The company's therapies works with the help of a bio marker discovery platform, enabling healthcare professionals to receive advanced treatment procedures of pancreatic cancer and liver metastases.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • GIGA EE1 Tower
  • Avenue Hippocrate 5
  • 4000 Liège
  • Belgium
+32 04 000 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Targetome Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 01-Apr-2018 00.000 Completed Out of Business
4. Grant 29-Feb-2016 00000 00.000 Completed Generating Revenue
3. Early Stage VC 09-Oct-2015 00000 00.000 00.000 Completed Generating Revenue
2. Early Stage VC 26-Jul-2013 $1.08M $1.08M 00.000 Completed Generating Revenue
1. Accelerator/Incubator 01-Sep-2011 Completed Generating Revenue
To view Targetome’s complete valuation and funding history, request access »

Targetome Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Class G 0,000 0000.00 0000.00 00 0000.00 00.000
Class F 000 0000.00 0000.00 00 0000.00 00.000
Class C 000 0000.00 0000.00 00 0000.00 0.000
Preference 2,252 $336.88 $336.88 1x $336.88 40.02%
Preference 500 $336.88 $336.88 1x $336.88 8.89%
To view Targetome’s complete cap table history, request access »